Publications by Michael Groessl

Ligand substitutions between ruthenium-cymene compounds can control protein versus DNA targeting and anticancer activity

Paul Joseph Dyson, Ursula Röthlisberger, Wee Han Ang, Pablo Campomanes Ramos, Alexey Nazarov, Michael Groessl, Catherine Marie Amélie Clavel

Ruthenium compounds have become promising alternatives to platinum drugs by displaying specific activities against different cancers and favourable toxicity and clearance properties. Nonetheless, their molecular targeting and mechanism of action are poorly ...

Nature Research2014

Multinuclear Cytotoxic Metallodrugs: Synthesis and Biological Studies of Novel Bimetallic Titanium-Ruthenium and Gold Complexes

Alexey Nazarov, Angela Casini, Michael Groessl, Olivier Pierre Zava

Springer2014

Application of mass spectrometric techniques to delineate the modes-of-action of anticancer metallodrugs

Paul Joseph Dyson, Christian Hartinger, Angela Casini, Michael Groessl

Mass spectrometry (MS) has emerged as an important tool for studying anticancer metallodrugs in complex biological samples and for characterising their interactions with biomolecules and potential targets on a molecular level. The exact modes-of-action of ...

Royal Society of Chemistry2013

Synthesis and characterization of a new class of anti-angiogenic agent based on ruthenium clusters

Hubert van den Bergh, Paul Joseph Dyson, Patrycja Nowak-Sliwinska, Alexey Nazarov, Michael Groessl, Olivier Pierre Zava, Mathurin Baquié

New triruthenium-carbonyl clusters derivatized with glucose-modified bicyclophosphite ligands have been synthesized. These compounds were found to have cytostatic and cytotoxic activity and depending on the number of bicyclophosphite ligands, and could be ...

Nature Publishing Group2013

Maleimide-functionalised organoruthenium anticancer agents and their binding to thiol-containing biomolecules

Paul Joseph Dyson, Yury Tsybin, Christian Hartinger, Alexey Nazarov, Michael Groessl, Muhammad Hanif

Ru-II(arene) anticancer compounds with maleimide functionality were prepared to allow selective interaction with thiol-containing biomolecules and thereby enforcing the selective delivery of the compounds to the tumour. ...

Royal Society of Chemistry2012

Combination of metallomics and proteomics to study the effects of the metallodrug RAPTA-T on human cancer cells

Paul Joseph Dyson, Michael Groessl

An approach to characterize the interactions of RAPTA-T, a novel ruthenium-based anticancer drug candidate with intriguing antimetastatic properties, with human ovarian cancer cells in vitro is described. The distribution profile of the metallodrug within ...

Royal Society of Chemistry2012

Anthracene-Tethered Ruthenium(II) Arene Complexes as Tools To Visualize the Cellular Localization of Putative Organometallic Anticancer Compounds

Rosario Scopelliti, Paul Joseph Dyson, Wee Han Ang, Julie Risse, Christian Hartinger, Alexey Nazarov, Michael Groessl, Olivier Pierre Zava, Albert Ruggi, Frédéric Schmitt

Anthracene derivatives of ruthenium(II) arene compounds with 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (pta) or a sugar phosphite ligand, viz., 3,5,6-bicyclophosphite1,2-O-isopropylidene-alpha-D-glucofuranoside, were prepared in order to evaluate their ...

2012

A Ruthenium Antimetastasis Agent Forms Specific Histone Protein Adducts in the Nucleosome Core

Paul Joseph Dyson, Christian Hartinger, Michael Groessl

2011

Mass Spectrometric and Theoretical Study of Polyiodides: The Connection between Solid State, Solution, and Gas Phases

Paul Joseph Dyson, Zhaofu Fei, Michael Groessl

Polyiodides have been transferred intact from acetonitrile solution to the gas phase and analyzed by mass spectrometry. A range of ions were observed, including I-11, I-13, and I-15, which have higher iodine/iodide ratios than any previously ...

2011

Cellular uptake and subcellular distribution of ruthenium-based metallodrugs under clinical investigation versus cisplatin

Paul Joseph Dyson, Michael Groessl, Olivier Pierre Zava

The cellular uptake and subcellular distribution including adduct formation with genomic DNA and uptake into mitochondria of two ruthenium(III)-based drugs in clinical trials, KP1019 and NAMI-A, and cisplatin, was investigated in cisplatin sensitive and re ...

2011

Multinuclear Cytotoxic Metallodrugs: Physicochemical Characterization and Biological Properties of Novel Heteronuclear Gold-Titanium Complexes

Philippe Richard, Angela Casini, Michael Groessl, Olivier Pierre Zava

An unprecedented series of titanocene-gold bi- and trimetallic complexes of the general formula [(eta(5)-C5H5)-(mu-eta(5):kappa(1)-C5H4(CH2)(n)PPh2)TiCl2AuClx](q+) (n = 0, 2, or 4; m = 1, x =1, q = 0 or m = 2, x = 0, q = 1) have been prepared and char ...

2011

Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry

Paul Joseph Dyson, Yury Tsybin, Christian Hartinger, Michael Groessl

The binding of the ruthenium-based anticancer drug candidates KP1019, NAMI-A and RAPTA-T towards different double-stranded oligonucleotides was probed by electrospray ionisation mass spectrometry and compared with that of the widely used platinum-based che ...

Springer-Verlag2010

Reactivity of anticancer metallodrugs with serum proteins: New insights from size exclusion chromatography-ICP-MS and ESI-MS

Paul Joseph Dyson, Angela Casini, Michael Groessl

A method based on the coupling of high resolution size-exclusion liquid chromatography using a polymer stationary phase with inductively coupled plasma mass spectrometry was developed to study the interactions of two metallodrugs - cisplatin and RAPTA-T - ...

Royal Society of Chemistry2010

Phosphonium and Ammonium Ionic Liquids with Aromatic Anions: Synthesis, Properties, and Platinum Extraction

Michael Groessl

Several hydrophobic long-chain quaternary ammonium and phosphonium ionic liquids (ILs) with functionalized aromatic anions were prepared following a metathesis route using tricaprylmethylammonium chloride (Aliquat 336) and trihexyl(tetradecyl) phosphonium ...

2010

Proteins as Possible Targets for Cytotoxic trans-Platinum(II) Complexes with Aliphatic Amine Ligands: Further Exceptions to the DNA Paradigm

Paul Joseph Dyson, Angela Casini, Michael Groessl

The reactivity of three cytotoxic trans-PtII complexes bearing aliph. amine ligands, with transferrin and single-stranded oligonucleotides as DNA models, was investigated by ESI-MS and the results obtained are discussed in comparison with cisplatin. Tandem ...

Wiley-Blackwell2010

Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity

Kay Severin, Christian Hartinger, Alexey Nazarov, Michael Groessl

Multinuclear platinum anticancer complexes are a proven option to overcome resistance of established anticancer compounds. Transferring this concept to ruthenium complexes led to the synthesis of dinuclear Ru(II)-arene compounds containing a bis(pyridinone ...

2009

A Novel Cytotoxic Cerium Complex: Aquatrichloridobis(1,10-phenanthroline)cerium(III) (KP776). Synthesis, Characterization, Behavior in H2O, Binding towards Biomolecules, and Antiproliferative Activity

Michael Groessl

The lanthanide complex aquatrichloridobis(1,10-phenanthroline)cerium(III) [Ce(phen)(2)(H2O)Cl-3] (KP776) was fully characterized by elemental analysis, IR-, and H-1- and C-13-NMR spectroscopy, as well as TG/DTA measurements, and its behavior in H2O, import ...

2009

Capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry: A novel approach for the analysis of anticancer metallodrugs in human serum and plasma

Christian Hartinger, Michael Groessl

The development of metal-based chemotherapeutics lacks methods which are capable of providing early indication on the potential of new metal complexes as future anticancer drugs. Since most of these compounds are administered intravenously, serum proteins ...

2008

CZE-ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP

Paul Joseph Dyson, Christian Hartinger, Michael Groessl

Elucidating the mode of action and thereby opening the way to the design of chemotherapeutic agents is one of the major goals of metal-based anticancer research. Hydrolysis and DNA binding play an important role for pharmaceutical formulation and for exert ...

2008

Elucidation of the interactions of an anticancer ruthenium complex in clinical trials with biomolecules utilizing capillary electrophoresis hyphenated to inductively coupled plasma-mass spectrometry

Paul Joseph Dyson, Christian Hartinger, Michael Groessl

The application of capillary electrophoresis (CE) combined with highly sensitive inductively-coupled-plasma mass spectrometric (ICP-MS) detection allows the interactions of metal complexes with biomols. to be characterized. This technique has been used to ...

2008